Triple-Targeting Delivery of CRISPR/Cas9 to Reduce the Risk of Cardiovascular Diseases
出版年份 2019 全文链接
标题
Triple-Targeting Delivery of CRISPR/Cas9 to Reduce the Risk of Cardiovascular Diseases
作者
关键词
-
出版物
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-07-18
DOI
10.1002/anie.201903618
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Thermo-triggered Release of CRISPR-Cas9 System by Lipid-Encapsulated Gold Nanoparticles for Tumor Therapy
- (2018) Peng Wang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- PCSK9
- (2018) Michael D. Shapiro et al. CIRCULATION RESEARCH
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
- (2018) Jonathan D. Finn et al. Cell Reports
- The construction of drug-resistant cancer cell lines by CRISPR/Cas9 system for drug screening
- (2018) Lingmin Zhang et al. Science Bulletin
- Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
- (2017) Xue Gao et al. NATURE
- Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes
- (2017) Brett T Staahl et al. NATURE BIOTECHNOLOGY
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core-Shell Nanocarrier
- (2017) Peng Wang et al. Advanced Science
- Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair
- (2017) Kunwoo Lee et al. Nature Biomedical Engineering
- Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA
- (2016) Jason B. Miller et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Efficient Intracellular Delivery of Native Proteins
- (2015) Diego S. D’Astolfo et al. CELL
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
- (2015) Nathalie Bergeron et al. CIRCULATION
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
- (2015) Jean-Charles Nault et al. NATURE GENETICS
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic
- (2014) Fotios Barkas et al. ANGIOLOGY
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- CRISPR-mediated direct mutation of cancer genes in the mouse liver
- (2014) Wen Xue et al. NATURE
- Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
- (2014) John A Zuris et al. NATURE BIOTECHNOLOGY
- A Highly Efficient Synthetic Vector: Nonhydrodynamic Delivery of DNA to Hepatocyte Nuclei in Vivo
- (2013) Yunxia Hu et al. ACS Nano
- Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity
- (2013) F. Ann Ran et al. CELL
- PCSK9—an exciting target for reducing LDL-cholesterol levels
- (2013) D. John Betteridge Nature Reviews Endocrinology
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started